848366-38-1

Basic information

• Product Name: 6-Chloro-N-methylpyrazin-2-amine
• Synonyms: 2-Chloro-6-(methylamino)pyrazine;6-Chloro-N-methylpyrazin-2-amine;2-PyrazinaMine, 6-chloro-N-Methyl-
• CAS NO: 848366-38-1
• Molecular Formula: C₅H₆ClN₃
• Molecular Weight: 143.58
• Product Categories: Amines;blocks
• Mol File: 848366-38-1.mol

Chemical Properties

• Boiling Point: 250.4 °C at 760 mmHg
• Flash Point: 105.2 °C
• Appearance: /
• Density: 1.338 g/cm³
• Vapor Pressure: 0.0218mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: 2-8°C(protect from light)
• PKA: 1.07±0.25(Predicted)
• CAS DataBase Reference: 6-Chloro-N-methylpyrazin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-N-methylpyrazin-2-amine(848366-38-1)
• EPA Substance Registry System: 6-Chloro-N-methylpyrazin-2-amine(848366-38-1)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 848366-38-1(Hazardous Substances Data)

Usage

Uses

2-Chloro-6-methylaminopyrazine

InChI:InChI=1/C5H6ClN3/c1-7-5-3-8-2-4(6)9-5/h2-3H,1H3,(H,7,9)

Upstream product

• 4774-14-5 2,6-dichloropyrazine 
• 74-89-5 methylamine 

Downstream Products

• 848366-44-9 3,5-dibromo-6-chloro-N-methylpyrazin-2-amine 

Relevant articles and documents

Xanthate-mediated intermolecular alkylation of pyrazines

An expedient approach for the intermolecular C-H functionalization of pyrazines and other heteroarenes by the radical chemistry of xanthates is reported. Incorporation of a multitude of functional alkyl groups onto these heteroarenes proceeds in good yiel

CRF1 RECEPTOR LIGANDS COMPRISING FUSED BICYCLIC HETEROARYL MOIETIES

Substituted heteroaryl fused pyridine, pyrazine, and related heterobicyclic compounds that act as selective modulators of CRF1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, gastrointestinal disorders, and eating disorders. Methods of treatment of such disorders as well as packaged pharmaceutical compositions are also provided. Compounds provided herein are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.